Key statistics
As of last trade BioLine RX Ltd (YP2A:DEU) traded at 0.308, 4.05% above its 52-week low of 0.296, set on Oct 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.505 |
---|---|
High | 0.600 |
Low | 0.308 |
Bid | 0.278 |
Offer | 0.34 |
Previous close | 0.52 |
Average volume | 6.15k |
---|---|
Shares outstanding | 79.99m |
Free float | 79.99m |
P/E (TTM) | -- |
Market cap | 34.40m USD |
EPS (TTM) | -0.7628 USD |
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Press releases
- BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
- BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
- BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
- BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
- BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection
More ▼